MANE

Veradermics, Incorporated
$96.20
+28.36 (+41.80%)
Mkt Cap 3.25B
Volume 2,803,726
52W Range 32-87.45
Sector Healthcare
Beta 0.00
EPS (TTM) -0.14
P/E Ratio -286.94
Revenue (TTM) 0
Rev Growth (5Y) N/A
EPS Growth (5Y) N/A

Company Description

Track Record

Showing latest 4 periods • Swipe for more
Metric 2024 2023
Revenue 0 0
Net Income (26.49M) (16.49M)
EPS -0.14 -0.08
Free Cash Flow (23.69M) (13.51M)
FCF / Share -0.12 -0.07
Operating CF (23.69M) (13.51M)
Total Assets 59.38M 18.46M
Total Debt 0 786,000
Cash & Equiv 53.08M 16.30M
Book Value 54.66M 14.62M
Return on Equity -0.48 -1.13
MANE News
MANE (NYSE:MANE) Receives Average Rating of “Moderate Buy” from Analysts
Apr 24, 2026 12:48 AM · defenseworld.net
Veradermics Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Corporate and Clinical Updates
Mar 30, 2026 03:30 AM · businesswire.com
Veradermics Announces Presentations on VDPHL01 and Patient Experiences With Pattern Hair Loss at 2026 American Academy of Dermatology Annual Meeting
Mar 18, 2026 03:00 AM · businesswire.com
Veradermics, Incorporated (MANE) Presents at Leerink Global Healthcare Conference 2026 Transcript
Mar 16, 2026 04:42 PM · seekingalpha.com
Analysts Set MANE (NYSE:MANE) Target Price at $78.33
Mar 07, 2026 08:11 PM · defenseworld.net
Veradermics to Participate in Upcoming March Investor Conferences
Mar 03, 2026 02:00 AM · businesswire.com
Veradermics eyes FDA first as Jefferies initiates at 'buy'; sees 75% upside on oral hair loss pill
Mar 02, 2026 08:16 AM · proactiveinvestors.com
Reddit, KKR, and 2 Biotech IPOs Seeing the Love From Insiders
Feb 16, 2026 03:40 AM · 247wallst.com
NYSE Content Update: Forgent Power Solutions, Post IPO, to Ring Opening Bell
Feb 12, 2026 03:55 AM · prnewswire.com
First Look: Novo sues Hims, BP halts buybacks, Meta faces trial
Feb 10, 2026 02:39 AM · gurufocus.com